Search company, investor...


Founded Year



Acquired | Acquired

Total Raised




About Evalve

Evalve is a medical device company seeking to revolutionize the treatment of mitral valve disease with a minimally invasive approach. On September 11th, 2009, Evalve was acquired by Abbott.

Headquarters Location

4045 Campbell Avenue

Menlo Park, California, 94025,

United States


Missing: Evalve's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Evalve's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Evalve Patents

Evalve has filed 138 patents.

The 3 most popular patent topics include:

  • Cardiac anatomy
  • Cardiac surgery
  • Valvular heart disease
patents chart

Application Date

Grant Date


Related Topics




Cardiac anatomy, Cardiac surgery, Congenital heart defects, Veins of the torso, Cardiology


Application Date


Grant Date



Related Topics

Cardiac anatomy, Cardiac surgery, Congenital heart defects, Veins of the torso, Cardiology



Latest Evalve News

Avive Solutions raises $7 million

Jun 26, 2020

Avive Solutions, the company focused on addressing the global public health issue of Sudden Cardiac Arrest, has raised $7 million in funding, bringing the total raised to over $15 Million since the Company’s inception in 2017. This round was led by new investor, Laerdal Million Lives Fund, with participation from Kenko Venture Partners, Irish Angels, and numerous renowned medical device executives and healthcare leaders from current and past companies such as ResMed, Hill-Rom, Evalve, and Northwestern Health. With national average survival rates of <10%, SCA accounts for over 350,000 out of hospital deaths per year in the US, and it is the leading cause of death of people over age 40, and the leading cause of death for student-athletes. While CPR can help to “buy time,” a person in SCA must ultimately receive a high energy defibrillation shock delivered from an AED to survive, and every minute that a person goes without receiving a defibrillation shock reduces their chances of survival. The California-based startup is developing a “next-generation” automated external defibrillator and software solutions for out of hospital cardiac arrest response in an effort to increase survival rates. “Over the past two decades, despite the AED industry deploying millions of units throughout the U.S., there has been no meaningful increase in SCA survival rates across the country. For more than 20 years, the industry’s status quo approach to addressing this significant problem has been to deploy more and more hardware that has modest incremental feature improvements, without addressing the true problem that is inhibiting tens of thousands of additional lives from being saved every year – which is simply getting AEDs where they are needed, when they are needed.” – Sameer Jafri, cofounder and president of Avive Solutions. “By bringing data-driven connectivity in the form of an integrated software and device platform, we believe Avive can play a meaningful role across the Chain of Survival for cardiac arrest. By building a superior AED which includes features that create accessible CPR training, and developing a new system to improve rapid defibrillation, while also creating a data link to professional first responders, we are excited about the life-saving technology and opportunity Avive has in front of them, and we are passionate about helping them bring their product to millions of SCA patients.” – Jeff Trost, Managing Partner of Laerdal Million Lives Fund. Share this A really good email covering top news. Leave this field empty if you're human:

Evalve Frequently Asked Questions (FAQ)

  • When was Evalve founded?

    Evalve was founded in 1999.

  • Where is Evalve's headquarters?

    Evalve's headquarters is located at 4045 Campbell Avenue, Menlo Park.

  • What is Evalve's latest funding round?

    Evalve's latest funding round is Acquired.

  • How much did Evalve raise?

    Evalve raised a total of $117.4M.

  • Who are the investors of Evalve?

    Investors of Evalve include Abbott, New Enterprise Associates, Cutlass Capital, ABS Ventures, Delphi Ventures and 14 more.

  • Who are Evalve's competitors?

    Competitors of Evalve include Cardiac Dimensions, NeoChord, Endologix, NxThera, Intact Medical, Symetis, Torax Medical, Cabochon Aesthetics, Articulinx, Cardiosolutions and 18 more.

Compare Evalve to Competitors


DuoCure offers intraluminal minimally invasive implantable device for treatment of obesity.


Researcher and developer of a minimally invasive, encapsulated cellular transplant device for the treatment of diabetes. The company sold its assets to Novocell.

Endologix Logo

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

NeoChord Logo

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.

MicroTransponder Logo

MicroTransponder is a global medical device company committed to developing research-based neuroscience solutions. The company focuses on restoring independence and dignity for people suffering from neurological conditions that impair sensory and motor function. MicroTransponder's FDA-approved Vivistim® Paired VNS™ System is a clinically-proven medical technology that generates more improvement in upper limb function than rehabilitation alone for stroke survivors after 6 weeks of in-clinic therapy. MicroTransponder was founded in 2007 and is based in Austin, Texas.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.